FRM-6124 Trials Halted

There is a highly credible report that the Forum Pharmaceuticals Phase III trials for encenicline/FRM-6124 are being halted due to a safety issue: Gastric hypomotility setting the stage for eventual gut perforation. FRM-6124 is a program that NIR has long followed, and while there have been questions raised regarding the magnitude of its procognitive impact, we have seen it as one of the more promising options for cognition in Alzheimer’s and schizophrenia, the one clinical-stage nicotinic alpha 7 modulator still left standing. Forum has not yet made a public announcement, we await any detail that may come from them on this. But in the meantime, this would be devastating news. It would leave the 5HT-6 antagonist programs from Lundbeck/Otsuka and Axovant  as the most advanced procognitive candidates for Alzheimer’s. Unless and until a disease-modifier establishes efficacy in the Alzheimer’s realm, and nothing has yet produced a clearcut, consistent signal, symptomatic therapies will continue to receive clinical and investor emphasis, even if their magnitude of clinical effect is marginal–so long as they exert that effect safely. It appears that FRM-6124 has failed that critical test.

Addendum: Forum’s press release was finally sent out, and it provided some additional detail regarding the Phase III programs: The Alzheimer’s programs have been fully suspended, no additional study drug will be administered during the clinical hold.
The schizophrenia efficacy trials, which are fully enrolled, will continue, with additional GI safety monitoring provided. The premise is that elderly Alzheimer’s patients, who have a documented elevated incidence of GI disorders, may be particularly–or even uniquely– vulnerable to this AE. No patients in the schizophrenia trials have shown this AE (they have an average age of 40) hence the decision to allow the completion of the two efficacy trials. However, a longterm safety study in CIAS was halted, so the FDA is hedging their bets regarding FRM-6124’s safety in even the younger CIAS population.

This entry was posted in Biotech, Science and tagged , , , , , . Bookmark the permalink.

One Response to FRM-6124 Trials Halted

  1. mike guiltinan says:

    This months JAMA shows QDM results in P2 for Alz with Agitation. This 220 patient 10 week trial the QDM arm scored a p=.053 for MMSE. There was another paper out in March that says DM acts on amps. Is DM a ampakine?
    Abstract
    Dextromethorphan (DM) is an antitussive with rapid acting antidepressant potential based on pharmacodynamic similarities to ketamine. Building upon our previous finding that DM produces antidepressant-like effects in the mouse forced swim test (FST), the present study aimed to establish the antidepressant-like actions of DM in the tail suspension test (TST), another well-established model predictive of antidepressant efficacy. Additionally, using the TST and FST, we investigated the role of α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors in the antidepressant-like properties of DM because accumulating evidence suggests that AMPA receptors play an important role in the pathophysiology of depression and may contribute to the efficacy of antidepressant medications, including that of ketamine. We found that DM displays antidepressant-like effects in the TST similar to the conventional and fast acting antidepressants characterized by imipramine and ketamine, respectively. Moreover, decreasing the first-pass metabolism of DM by concomitant administration of quinidine (CYP2D6 inhibitor) potentiated antidepressant-like actions, implying DM itself has antidepressant efficacy. Finally, in both the TST and FST, pretreatment with the AMPA receptor antagonist NBQX (2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide) significantly attenuated the antidepressant-like behavior elicited by DM. Together, the data show that DM exerts antidepressant-like actions through AMPA receptors, further suggesting DM may act as a safe and effective fast acting antidepressant drug.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s